Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study

Background: In Japan, eicosapentaenoic acid ethyl ester (EPA-E) is administered twice-daily or three-times-daily for dyslipidemia. We have developed MND-2119, a novel self-emulsifying formulation of highly purified EPA-E which can be administered once-daily. Objective: The objective of this study was to investigate the safety and efficacy of long-term admin-istration of MND-2119 in hypertriglyceridemia patients. Methods: In this multicenter, 52-week, open-label study, patients with high triglyceride (TG) (TG levels between >= 150 and < 500 mg/dL) undergoing lifestyle modification were randomized to MND-2119 2 g/day (n = 61) or MND-2119 4 g/day (n = 61). Results: The incidence of adverse events in MND-2119 2 g/day and MND-2119 4 g/day was 70.5% and 62.3%, respectively, and the incidence of adverse drug reactions was 9.8% and 8.2%, respectively. There were no notable problems in the safety assessments of both treatment groups. By Week 4, TG levels had decreased from baseline in both groups, and the TG reducing effect continued up to Week 52 (mean percentage change from baseline in TG at Week 52 [two-sided 95% confidence interval]: MND-2119 2 g/day:-16.71% [-26.61,-6.81], MND-2119 4 g/day:-21.01% [-27.86,-14.16]). In both groups, plasma EPA concentration at Week 4 was maintained up until Week 52 and the plasma EPA concentration at Week 52 was 200.5 +/- 54.7 mu g/mL in MND-2119 2 g/day and 308.6 +/- 98.6 mu g/mL in MND-2119 4 g/day. Conclusion: Long-term administration of MND-2119 was not associated with any safety-related problems. TG levels decreased by Week 4, and the TG reducing effect continued up to Week 52. (c) 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.